This article presents ongoing research at VIDO-InterVac for the development of safer and more effective adjuvants. These include adjuvants that stimulate innate immunity in the body and combination adjuvants.
Shirley Toms
Advertisement
Shirley Toms is a corporate communication manager at VIDO-InterVac
Articles by Shirley Toms
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
5